.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its best biopharma selection for 2025 as well as rated another 9 titles in the space as overweight. The assets banking company pointed out in a keep in mind that it remains to feel “diabesity is readied to become.